A Randomised Controlled Trial Of Factor Replacement Therapy In Snake Bite Coagulopathy
Funder
National Health and Medical Research Council
Funding Amount
$715,730.00
Summary
This proposal seeks funding to undertake a controlled trial of clotting factor replacement in snake bite coagulopathy after the administration of a neutralising dose of antivenom. The aim is to determine if factor replacement will result in a rapid return of clotting function in patients and therefore reduce the potential risk of major bleeding. This study will have international implications because globally snakebite coagulopathy is a major cause of morbidity and death like in Australia.
Validating Novel Serum Markers Of Neurodegeneration In Multiple Sclerosis Patients.
Funder
National Health and Medical Research Council
Funding Amount
$516,304.00
Summary
In multiple sclerosis (MS), permanent disability occurs when brain cells known as neurons are damaged following an immune attack. Current treatments reduce the number and severity of immune attacks, but they do not prevent neuron damage or permanent disability in many patients. There is currently no direct way to measure neuron damage in humans, so it is difficult to develop new drugs to prevent it. To address this need, we will trial a new blood test for measuring neuron damage in MS patients.
Does Fresh Frozen Plasma In Russells Viper Bite Coagulopathy Reduce The Dose And Duration Of Antivenom Therapy?
Funder
National Health and Medical Research Council
Funding Amount
$622,344.00
Summary
This proposal seeks funding to undertake a trial of clotting factor replacement with low dose antivenom therapy in snake bite coagulopathy in Sri Lanka. The aim is to determine if factor replacement will result in a rapid return of clotting function, allow a smaller dose of antivenom and therefore reduce the potential risk of major bleeding and reactions to antivenom. This study will have international implications because globally snakebite coagulopathy is a major cause of morbidity and death .